Javascript must be enabled to continue!
A Comprehensive Analysis of Cirrhotic Cardiomyopathy Among Patients with Liver Cirrhosis at Tertiary Care Hospital, Karachi
View through CrossRef
Objective: To determine the prevalence and complications of cirrhotic cardiomyopathy (CCM) in liver cirrhosis patients at a tertiary care hospital in Karachi, and to analyze associated factors contributing to disease progression.
Methodology: This descriptive study was conducted at the Department of Medicine, Civil Hospital Karachi, from October 2020 to April 2021. A total of 95 patients diagnosed with liver cirrhosis were included. Data was collected using a structured format and analyzed using SPSS. Stratification was applied to assess the relationship between cirrhotic cardiomyopathy and key factors such as age, gender, and duration of cirrhosis. The study used echocardiography to evaluate cardiac function, and pro-BNP levels were measured to assess the severity of cardiomyopathy.
Results: The mean age of the patients was 43.66±4.87 years, with a mean heart rate of 73.51±12.41 beats/min, pro-BNP levels of 78.63±7.37 pg/ml, and mean cirrhosis duration of 1.65±0.99 years. Of the 95 patients, 15 (15.8%) had cirrhotic cardiomyopathy, while 80 (84.2%) did not. Gender distribution showed 48 (50.5%) males and 47 (49.5%) females. Cirrhotic cardiomyopathy was more common in patients with longer disease duration and higher Child-Pugh scores, but the differences were not statistically significant.
Conclusion: Cirrhotic cardiomyopathy is a prevalent but often underdiagnosed complication in liver cirrhosis patients, with significant implications for disease management. Early diagnosis and monitoring are crucial to preventing adverse cardiovascular outcomes in cirrhosis patients.
Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad
Title: A Comprehensive Analysis of Cirrhotic Cardiomyopathy Among Patients with Liver Cirrhosis at Tertiary Care Hospital, Karachi
Description:
Objective: To determine the prevalence and complications of cirrhotic cardiomyopathy (CCM) in liver cirrhosis patients at a tertiary care hospital in Karachi, and to analyze associated factors contributing to disease progression.
Methodology: This descriptive study was conducted at the Department of Medicine, Civil Hospital Karachi, from October 2020 to April 2021.
A total of 95 patients diagnosed with liver cirrhosis were included.
Data was collected using a structured format and analyzed using SPSS.
Stratification was applied to assess the relationship between cirrhotic cardiomyopathy and key factors such as age, gender, and duration of cirrhosis.
The study used echocardiography to evaluate cardiac function, and pro-BNP levels were measured to assess the severity of cardiomyopathy.
Results: The mean age of the patients was 43.
66±4.
87 years, with a mean heart rate of 73.
51±12.
41 beats/min, pro-BNP levels of 78.
63±7.
37 pg/ml, and mean cirrhosis duration of 1.
65±0.
99 years.
Of the 95 patients, 15 (15.
8%) had cirrhotic cardiomyopathy, while 80 (84.
2%) did not.
Gender distribution showed 48 (50.
5%) males and 47 (49.
5%) females.
Cirrhotic cardiomyopathy was more common in patients with longer disease duration and higher Child-Pugh scores, but the differences were not statistically significant.
Conclusion: Cirrhotic cardiomyopathy is a prevalent but often underdiagnosed complication in liver cirrhosis patients, with significant implications for disease management.
Early diagnosis and monitoring are crucial to preventing adverse cardiovascular outcomes in cirrhosis patients.
Related Results
Frequency of Cirrhotic Cardiomyopathy Among Patients with Liver Cirrhosis
Frequency of Cirrhotic Cardiomyopathy Among Patients with Liver Cirrhosis
Introduction: Patients with liver cirrhosis may develop cirrhotic cardiomyopathy (CCM), a disorder marked by a compromised cardiac response to stress. Because of its mild clinical ...
Prolongation of QT Interval in ECG: A Hidden Complication of Cirrhotic Liver Disease
Prolongation of QT Interval in ECG: A Hidden Complication of Cirrhotic Liver Disease
Objective: To determine frequency of QT interval prolongation in ECG of patients with decompensated liver cirrhosis in a tertiary care hospital of Karachi, Pakistan.
Method...
Frequency of cirrhotic cardiomyopathy in decompensated liver cirrhosis patients.
Frequency of cirrhotic cardiomyopathy in decompensated liver cirrhosis patients.
Objective: To determine the frequency of cirrhotic cardiomyopathy in decompensated liver cirrhosis patients. Study Design: Descriptive, Cross-sectional. Setting: Department of Medi...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis
The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis
AbstractBackground and AimWe evaluated the characteristics of hepatocellular carcinoma (HCC) in patients who had non‐alcoholic fatty liver disease (NAFLD) without cirrhosis.Methods...
Multiple gastric red spots, capillary ectasia, hypergastrinemia and hypopepsinogenemia i in cirrhosis: A new syndrome?
Multiple gastric red spots, capillary ectasia, hypergastrinemia and hypopepsinogenemia i in cirrhosis: A new syndrome?
To characterize bleeding from gastric red spots in patients with cirrhosis, three groups of patients were studied: (a) 11 cirrhotic patients bleeding from gastric red spots, (b) 18...
Upper Gastrointestinal Cancer and Liver Cirrhosis
Upper Gastrointestinal Cancer and Liver Cirrhosis
The extended scope of upper gastrointestinal cancer can include esophageal cancer, gastric cancer and pancreatic cancer. A higher incidence rate of gastric cancer and esophageal ca...
Evolutive Aspects Of Patients With Cirrhosis After Harvoni Therapy
Evolutive Aspects Of Patients With Cirrhosis After Harvoni Therapy
Introduction: Cirrhosis, is a final pathway of chronic liver diseases. In recent years, Direct-Acting Antiviral Agents (DAAs) gained a leading role in the treatment of chronic hepa...

